Asset Details
Do you wish to reserve the book?
Phase 1/2 study of the WT 1 peptide cancer vaccine WT 4869 in patients with myelodysplastic syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase 1/2 study of the WT 1 peptide cancer vaccine WT 4869 in patients with myelodysplastic syndrome
Do you wish to request the book?
Phase 1/2 study of the WT 1 peptide cancer vaccine WT 4869 in patients with myelodysplastic syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase 1/2 study of the WT 1 peptide cancer vaccine WT 4869 in patients with myelodysplastic syndrome
2017
Overview
WT 4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 ( WT 1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT 4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT 4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3 + 3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score <1.5) red blood cell transfusion‐dependent patients with myelodysplastic syndrome. Twenty‐six patients were enrolled and treated (median age, 75 years; range, 32 to 89). The most common adverse event was injection site reaction (61.5%). Main grade 3 or 4 adverse events were neutropenia (30.8%), febrile neutropenia, pneumonia, elevated blood creatine phosphokinase levels and hypoalbuminemia (all 7.7%). Dose‐limiting toxicities occurred in 1 patient in the 50 μg/dose cohort (pyrexia, muscle hemorrhage and hypoalbuminemia) and 1 patient in the 400 μg/dose cohort (pneumonitis); however, the maximum tolerated dose could not be determined from this trial. The overall response rate was 18.2%, the disease control rate was 59.1% and median overall survival was 64.71 weeks (95% confidence interval: 50.29, 142.86) as assessed by the Kaplan–Meier method. Subgroup analysis of azacitidine‐refractory patients with higher‐risk myelodysplastic syndrome (11 patients) showed median overall survival of 55.71 weeks (approximately 13 months). WT 1‐specific cytotoxic T lymphocyte induction was observed in 11 of 25 evaluable patients. WT 4869 was well tolerated in patients with myelodysplastic syndrome and preliminary data suggest that WT 4869 is efficacious. This trial was registered at www.clinicaltrials.jp as Japic CTI ‐101374.
